GritBIO is the solution to the next generation of cancer therapeutics. Through the development of peptide technologies, which target the metabolism of cancer, GritBIO is able to offer a safer approach to treating squamous cell carcinoma of the pharynx. GritBIO is also currently researching novel biological inhibitors for SARS-CoV-2. The research currently being conducted positions our company at the cutting edge of solutions for today's most salient problems.